Abcam partnerships with companies and research organizations
Building strong partnerships to accelerate scientific discovery
We believe collaboration is at the heart of innovation and helps research move faster. Collaborating with partners allows us to deliver integrated solutions that empower researchers worldwide. The strength of our partnerships is impacting the pace of global discovery from research through to positive outcomes for human health.
We partner with a wide range of innovators and entrepreneurs, life science organizations, disease charities, pharmaceutical and biotechnology companies.
Our dedicated Business Development & Strategic Partnerships teams focus on both in-licensing and out-licensing:
- Our in-licensing and OEM activities enable us to expand our product offerings and capabilities, providing the clinical and life science communities with access to the latest biological reagents and associated support.
- Our out-licensing activities facilitate the use of our reagents by our partners for incorporation into their unique platforms. This initiative, known as “Abcam Inside”, enables our reagents to be used consistently across research, development, and clinical platforms, taking discoveries beyond research and into real-world solutions.
Benefits of partnering across your product development lifecycle
To explore partnership opportunities with us, fill in the form below and our team will get in touch
Holistic partnership advantages that reduce risk and drive long-term success
Flexible commercial frameworks and scalable partnership structures
- Tailored frameworks for every business type: From start-ups and RUO developers to CROs/CDMOs, platform builders (lateral flow, proteomics, spatial, multi-omics), and diagnostics programs.
- Built to de-risk and scale: Reduce validation risk and secure long-term, scalable supply through OEM, in‑/out‑licensing, and forecast-backed agreements.
Product performance and reproducibility
- Recombinant precision, end to end: Industry-leading recombinant antibodies with batch-to-batch consistency for precise, reproducible performance from discovery through to development.
- Rabbit monoclonal advantage: Superior affinity and specificity for challenging or weakly immunogenic targets. Higher-performing assays and sensitive detection.
Quality systems and regulated diagnostics readiness
- ISO 9001 certified: Rigorous quality systems that support applications, including laboratory-developed tests, improving lot-to-lot consistency and supply security, and helping reduce costly revalidation.
- ISO 13485 support for IVD workflows: Rabbit recombinant monoclonal antibodies manufactured under the Quality Management System ISO 13485 provides an adjacency to partners developing and manufacturing IVD medical devices.
Portfolio scale and custom development enablement
- Extensive licensable clone collection: Access a large portfolio of over 13,000 licensable clones validated across multiple applications, as well as unpublished sister clones, with scientific guidance for clone selection, product creation, and panel building.
- Custom development programs: Whole program support from target assessment to scale-up. Consultative guidance at every step, including conjugation, formulation, verification in your assays, and tech transfer.
Operational excellence and co-innovation for long-term growth
- Strategic partnership reliability: Enterprise-grade support through 90‑day rolling forecasts, capacity reservations, quote SLAs, and dedicated portal access, reducing operational risk and cost to serve for complex B2B programs.
- Collaborative innovation model: We co-innovate with partners by combining our predictive analytics, antibody pipeline, and governance framework to expand multiplex panels faster, de-risk biomarker selection, and unlock new revenue opportunities.
Our partners
Diagnostic partners
Proteomic partners
Scientific partners and consortia
